STORM Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brentuximab, an antibody targeting CD30.

Expansion Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Skyhawk Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Remix Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Arrakis Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Magnet Biomedicine 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Polatuzumab, an antibody targeting CD79B.

Cedilla Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tisotumab, an antibody targeting Tissue factor.

Cullgen 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mirvetuximab, an antibody targeting Folate receptor alpha.